1185-P: Maternal Exposure to Per- and Polyfluoroalkyl Substances and Risk of Adiposity in Offspring at Birth and Early Childhood—A Longitudinal Birth Cohort Study

Abstract

Introduction: Per- and polyfluoroalkyl substances (FPAS) are a class of man-made chemicals that cross the placenta. We examined the associations of maternal exposure to PFAS mixture with risk of adiposity in offspring at birth and childhood. Methods: In the perspective Hyperglycaemia-and-Adverse-Pregnancy-Outcome (HAPO) study, we measured serum concentrations of six PFAS biomarkers using high-performance LC-MS-MS in 1601 mothers who had joined the Hong Kong centre in 2002-2004 and 922 children at seven years old. We estimated PFAS burden score for each mother and child using concentrations of individual PFAS and exposure patterns of PFAS mixture. Adiposity in the offspring was defined by the ponderal-index (PI) at birth and sum-of-skinfold-thickness in mm at birth and childhood. We used linear regression to estimate associations of maternal exposure to PFAS mixture with adiposity risk. Results: PFAS burden score in pregnancy was positively associated with PI (β=0.50, 95% CI: 0.02, 0.97) and negatively associated with skinfold thickness (β=-0.61, 95% CI: -0.96, -0.27) in offspring at birth. The correlation of PFAS burden score in mothers and children at seven years old was weak (r=0.07). After adjusting for PFAS burden score of childhood, maternal PFAS burden score was negatively associated with skinfold-thickness in childhood (β=-2.29, 95% CI: -3.97, -0.62). Sex-specific analyses showed similar associations with PI in boys and girls at birth. In contrast, significant negative associations with skinfold thickness were observed in girls but not in boys at childhood. Conclusions: Maternal exposure to PFAS mixture is independently associated with risk of adiposity in offspring at birth. Its effect on childhood adiposity was apparent only in girls, not boys. Disclosure A.Yang: None. C.H.Tam: None. R.Ozaki: None. W.L.Lowe: None. B.E.Metzger: None. W.H.Tam: None. C.K.Wong: None. R.C.Ma: Advisory Panel; AstraZeneca, Merck & Co., Inc., Other Relationship; Bayer Inc., Boehringer-Ingelheim, Research Support; Tricida, Inc., Roche Diagnostics, Novo Nordisk. Funding Health and Medical Research Fund (13140761); Eunice Kennedy Shriver National Institute of Child Health and Human Development/National Institute of Diabetes and Digestive and Kidney Diseases (R01HD34242, R01HD34243); Research Grants Council of Hong Kong (473408, 471713)